Searching News Database: naltrexone
HSMN NewsFeed - 30 Aug 2023
Alkermes Announces Settlement With Teva Related to VIVITROL(R) Patent Litigation
Alkermes Announces Settlement With Teva Related to VIVITROL(R) Patent Litigation
HSMN NewsFeed - 27 Sep 2019
Currax(TM) Pharmaceuticals LLC Announces the Acquisition of Nalpropion Pharmaceuticals, Inc.
Currax(TM) Pharmaceuticals LLC Announces the Acquisition of Nalpropion Pharmaceuticals, Inc.
HSMN NewsFeed - 6 Aug 2018
US WorldMeds and Salix Announce U.S. Launch of LUCEMYRA(TM) (lofexidine) 0.18 Mg Tablets
US WorldMeds and Salix Announce U.S. Launch of LUCEMYRA(TM) (lofexidine) 0.18 Mg Tablets
HSMN NewsFeed - 1 Aug 2016
Orexigen Completes Acquisition of All U.S. Rights to Contrave(R) and Launches U.S. Sales Organization
Orexigen Completes Acquisition of All U.S. Rights to Contrave(R) and Launches U.S. Sales Organization
HSMN NewsFeed - 9 Jun 2016
Bradley Campbell, President and COO of Amicus Therapeutics, elected to Progenics Board of Directors
Bradley Campbell, President and COO of Amicus Therapeutics, elected to Progenics Board of Directors
HSMN NewsFeed - 8 Jun 2016
Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave(R) Patent Litigation
Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave(R) Patent Litigation
HSMN NewsFeed - 17 Mar 2016
Elite Announces U.S. FDA Priority Review Designation for SequestOx(TM) NDA
Elite Announces U.S. FDA Priority Review Designation for SequestOx(TM) NDA
HSMN NewsFeed - 29 Jan 2014
Progenics Pharmaceuticals Announces the Appointment of Karen Ferrante, M.D. to Its Board of Directors
Progenics Pharmaceuticals Announces the Appointment of Karen Ferrante, M.D. to Its Board of Directors
HSMN NewsFeed - 6 Feb 2013
Elite Pharmaceuticals Announces FDA Approval of Supplemental Application for Naltrexone
Elite Pharmaceuticals Announces FDA Approval of Supplemental Application for Naltrexone
HSMN NewsFeed - 18 Dec 2012
FDA Clears IND For First Clinical Trial Protocol Developed Using Crowdsourcing
FDA Clears IND For First Clinical Trial Protocol Developed Using Crowdsourcing
HSMN NewsFeed - 11 Oct 2012
Pfizer Announces Top-Line Results From A Phase 3 Long-Term Safety Study Of ALO-02:
Pfizer Announces Top-Line Results From A Phase 3 Long-Term Safety Study Of ALO-02:
HSMN NewsFeed - 30 Aug 2011
Progenics and Salix Announce FDA Acceptance of sNDA Filing for RELISTOR(R) in Patients with Non-Cancer Pain
Progenics and Salix Announce FDA Acceptance of sNDA Filing for RELISTOR(R) in Patients with Non-Cancer Pain
HSMN NewsFeed - 30 Mar 2011
Cara Therapeutics Announces Appointment of James B. Jones, M.D., Pharm.D., as Chief Medical Officer
Cara Therapeutics Announces Appointment of James B. Jones, M.D., Pharm.D., as Chief Medical Officer
HSMN NewsFeed - 17 Feb 2011
Orexigen(R) Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
Orexigen(R) Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
HSMN NewsFeed - 1 Feb 2011
FDA Issues Complete Response to New Drug Application for Contrave(R) for the Management of Obesity
FDA Issues Complete Response to New Drug Application for Contrave(R) for the Management of Obesity
HSMN NewsFeed - 5 Dec 2008
Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
HSMN NewsFeed - 26 Nov 2008
Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
HSMN NewsFeed - 4 Aug 2008
Alkermes Announces Approval of VIVITROL(R) for the Treatment of Alcohol Dependence in Russia
Alkermes Announces Approval of VIVITROL(R) for the Treatment of Alcohol Dependence in Russia
HSMN NewsFeed - 28 May 2008
New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
HSMN NewsFeed - 21 Apr 2008
Alpharma to Withdraw and Resubmit Its New Drug Application for EMBEDA(TM)
Alpharma to Withdraw and Resubmit Its New Drug Application for EMBEDA(TM)
HSMN NewsFeed - 14 Apr 2008
Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain
Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain
HSMN NewsFeed - 1 Apr 2008
Wyeth and Progenics Announce RELISTOR Receives Canadian Marketing Approval
Wyeth and Progenics Announce RELISTOR Receives Canadian Marketing Approval
HSMN NewsFeed - 31 Mar 2008
Acusphere Licenses Hydrophobic Drug Delivery System to Cephalon for $10 Million
Acusphere Licenses Hydrophobic Drug Delivery System to Cephalon for $10 Million
HSMN NewsFeed - 20 Mar 2008
Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
HSMN NewsFeed - 6 Mar 2008
inVentiv Selling Solutions Selected to Provide Sales Team for Cephalon Inc.
inVentiv Selling Solutions Selected to Provide Sales Team for Cephalon Inc.
HSMN NewsFeed - 19 Feb 2008
FDA Accepts TREANDA(R) New Drug Application for the Treatment of Relapsed Indolent Non-Hodgkin's Lymphoma
FDA Accepts TREANDA(R) New Drug Application for the Treatment of Relapsed Indolent Non-Hodgkin's Lymphoma
HSMN NewsFeed - 25 Jan 2008
Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
HSMN NewsFeed - 7 Jan 2008
Alkermes Announces Agreement for the Commercialization of VIVITROL in Russia/CIS
Alkermes Announces Agreement for the Commercialization of VIVITROL in Russia/CIS
HSMN NewsFeed - 11 Dec 2007
OREXIGEN(TM) Therapeutics Initiates Fourth Phase III Trial for Contrave(TM) to Treat Obesity
OREXIGEN(TM) Therapeutics Initiates Fourth Phase III Trial for Contrave(TM) to Treat Obesity
HSMN NewsFeed - 27 Nov 2007
Neuromed Appoints Jeffrey Arcara and Gene Wright to Senior Management Team
Neuromed Appoints Jeffrey Arcara and Gene Wright to Senior Management Team
HSMN NewsFeed - 1 Nov 2007
Cephalon Appoints Valli F. Baldassano as Executive Vice President and Chief Compliance Officer
Cephalon Appoints Valli F. Baldassano as Executive Vice President and Chief Compliance Officer
HSMN NewsFeed - 17 Oct 2007
OREXIGEN(TM) Therapeutics Initiates its Third Phase III Trial for Contrave(TM) to Treat Obesity
OREXIGEN(TM) Therapeutics Initiates its Third Phase III Trial for Contrave(TM) to Treat Obesity
HSMN NewsFeed - 21 Sep 2007
Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
HSMN NewsFeed - 13 Sep 2007
Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
HSMN NewsFeed - 29 Aug 2007
FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
HSMN NewsFeed - 29 Aug 2007
Wyeth and Progenics Submit Marketing Application in Australia for Subcutaneous Methylnaltrexone
Wyeth and Progenics Submit Marketing Application in Australia for Subcutaneous Methylnaltrexone
HSMN NewsFeed - 23 Aug 2007
Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
HSMN NewsFeed - 1 May 2007
Progenics Announces Positive Results in Clinical Trial of Novel HIV Therapy
Progenics Announces Positive Results in Clinical Trial of Novel HIV Therapy
HSMN NewsFeed - 25 Apr 2007
Alkermes and Indevus Announce Initiation of Phase 2a Clinical Study of ALKS 27 for the Treatment of COPD
Alkermes and Indevus Announce Initiation of Phase 2a Clinical Study of ALKS 27 for the Treatment of COPD
HSMN NewsFeed - 13 Apr 2007
FDA Approves New Dose of RISPERDAL(R) CONSTA(R) for Schizophrenia Treatment
FDA Approves New Dose of RISPERDAL(R) CONSTA(R) for Schizophrenia Treatment
HSMN NewsFeed - 26 Mar 2007
Cephalon Files Marketing Application for Approval of a Fentanyl Effervescent Buccal Tablet in Europe
Cephalon Files Marketing Application for Approval of a Fentanyl Effervescent Buccal Tablet in Europe
HSMN NewsFeed - 24 Jan 2007
Cephalon Comments on Study of its Leukemia Treatment Led by National Cancer Institute Cooperative Group
Cephalon Comments on Study of its Leukemia Treatment Led by National Cancer Institute Cooperative Group
HSMN NewsFeed - 9 Jan 2007
Cephalon Announces Positive Results from Two Phase 3 Clinical Trials of FENTORA(TM) in Breakthrough Pain
Cephalon Announces Positive Results from Two Phase 3 Clinical Trials of FENTORA(TM) in Breakthrough Pain
HSMN NewsFeed - 8 Jan 2007
Cephalon Announces Positive Results from Two Phase 3 Clinical Trials of FENTORA(TM) in Breakthrough Pain
Cephalon Announces Positive Results from Two Phase 3 Clinical Trials of FENTORA(TM) in Breakthrough Pain
HSMN NewsFeed - 8 Jan 2007
Progenics Pharmaceuticals Expands Senior Management Team and Board of Directors
Progenics Pharmaceuticals Expands Senior Management Team and Board of Directors
HSMN NewsFeed - 20 Dec 2006
Alkermes Announces Submission of New Drug Application for RISPERDAL(R) CONSTA(R) in Japan
Alkermes Announces Submission of New Drug Application for RISPERDAL(R) CONSTA(R) in Japan
HSMN NewsFeed - 27 Oct 2006
Elite Holds Clinical Guidance Meeting with the FDA on Its Abuse Deterrent Pain Program
Elite Holds Clinical Guidance Meeting with the FDA on Its Abuse Deterrent Pain Program
HSMN NewsFeed - 12 Sep 2006
Elite Pharmaceuticals Provides Update on Company's Progress and Projected Milestones
Elite Pharmaceuticals Provides Update on Company's Progress and Projected Milestones
HSMN NewsFeed - 26 Jun 2006
Cephalon Announces Results from GABITRIL(R) Clinical Program in Generalized Anxiety Disorder
Cephalon Announces Results from GABITRIL(R) Clinical Program in Generalized Anxiety Disorder
Additional items found! 48
Members Archive contains
48 additional stories matching:
naltrexone
(Password required)
naltrexone
(Password required)